Top ▲
Target id: 1874
Nomenclature: CD40
Systematic Nomenclature: TNFRSF5
Family: Immune checkpoint catalytic receptors, Tumour necrosis factor (TNF) receptor family
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 1 | 277 | 20q13.12 | CD40 | CD40 molecule | |
Mouse | 1 | 289 | 2 85.38 cM | Cd40 | CD40 antigen | |
Rat | - | - | Cd40 | CD40 molecule |
Previous and Unofficial Names |
CD40 molecule, TNF receptor superfamily member 5 | TNFRSF5 |
Database Links | |
Alphafold | P25942 (Hs), P27512 (Mm) |
ChEMBL Target | CHEMBL1250358 (Hs) |
Ensembl Gene | ENSG00000101017 (Hs), ENSMUSG00000017652 (Mm), ENSRNOG00000018488 (Rn) |
Entrez Gene | 958 (Hs), 21939 (Mm), 171369 (Rn) |
Human Protein Atlas | ENSG00000101017 (Hs) |
KEGG Gene | hsa:958 (Hs), mmu:21939 (Mm), rno:171369 (Rn) |
OMIM | 109535 (Hs) |
Pharos | P25942 (Hs) |
UniProtKB | P25942 (Hs), P27512 (Mm) |
Wikipedia | CD40 (Hs) |
Natural/Endogenous Ligands |
CD40 ligand {Sp: Human} |
Adaptor proteins (Human) |
TRAF1, TRAF2, TRAF3, TRAF5, TRAF6 |
Download all structure-activity data for this target as a CSV file
Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Antibody Comments | |||||||||||||||||||||||||||||||||||||||||||||||||||
Other anti-CD40 mAbs in clinical development include ABBV-323 (ravagalimab; for Crohn's disease) and JNJ-64457107 (vanalimab, ADC-1013; a CD40 agonistic mAb in Phase 1 immuno-oncology trial NCT02829099) |
Other Binding Ligands | |||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
CD40 is a stimulatory receptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF). It is expressed on a variety of immune cells, including macrophages, B cells, and dendritic cells (DCs). CD40 plays a key role in the activation of the immune system. Endogenous ligand is CD154 (CD40L) on TH cells. CD40 is an immunotherapy and immuno-oncology clinical target. Anti-CD40 agonistic monoclonal antibodies that induce activation and proliferation of effector and memory T cells, and enhance the immune response against tumour cells, are in clinical development. |
Immuno Process Associations | ||
|
||
|
||
|
||
|
||
|
||
|
||
|
1. Heusser C, Rush J, Vincent K. (2012) Silent fc variants of anti-cd40 antibodies. Patent number: WO2012065950. Assignee: Novartis Ag. Priority date: 15/11/2010. Publication date: 24/05/2012.